

1 REFERENCES

- 2 1. Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, et al. Acquired
3 hemophilia A in the United Kingdom: a 2-year national surveillance study by the United
4 Kingdom Haemophilia Centre Doctors' Organisation. *Blood*. 2007;109(5):1870-7.
- 5 2. Tiede A, Collins P, Knoebl P, Teitel J, Kessler C, Shima M, et al. International
6 recommendations on the diagnosis and treatment of acquired hemophilia A. *Haematologica*.
7 2020;105(7):1791-801.
- 8 3. Tiede A, Klamroth R, Scharf RE, Trappe RU, Holstein K, Huth-Kühne A, et al.
9 Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from
10 the GTH-AH 01/2010 study. *Blood*. 2015;125(7):1091-7.
- 11 4. Knoebl P, Marco P, Baudo F, Collins P, Huth-Kühne A, Nemes L, et al.
12 Demographic and clinical data in acquired hemophilia A: results from the European Acquired
13 Haemophilia Registry (EACH2). *Journal of thrombosis and haemostasis : JTH*.
14 2012;10(4):622-31.
- 15 5. Sampei Z, Igawa T, Soeda T, Okuyama-Nishida Y, Moriyama C, Wakabayashi T, et
16 al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody
17 mimicking the function of factor VIII cofactor activity. *PLoS One*. 2013;8(2):e57479.
- 18 6. Shima M, Amano K, Ogawa Y, Yoneyama K, Ozaki R, Kobayashi R, et al. A
19 prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients
20 with acquired hemophilia A. *Journal of thrombosis and haemostasis : JTH*. 2023;21(3):534-
21 45.
- 22 7. Tiede A, Kemkes-Matthes B, Knoebl P. Should Emicizumab Be Used in Patients with
23 Acquired Hemophilia A? *Journal of thrombosis and haemostasis : JTH*. 2020.
- 24 8. Salaj P, Geierová V, Ivanová E, Loužil J, Pohlreichová V, Hrachovinová I, et al.
25 Identifying risk factors and optimizing standard of care for patients with acquired haemophilia
26 A: Results from a Czech patient cohort. *Haemophilia : the official journal of the World
27 Federation of Hemophilia*. 2020;26(4):643-51.
- 28 9. Ohde S, Hayashi A, Takahasi O, Yamakawa S, Nakamura M, Osawa A, et al. A 2-
29 week prognostic prediction model for terminal cancer patients in a palliative care unit at a
30 Japanese general hospital. *Palliat Med*. 2011;25(2):170-6.
- 31 10. Salim AA, Kawasoe S, Kubozono T, Ojima S, Kawabata T, Hashiguchi H, et al.
32 Development of predictive equation and score for 5-year metabolic syndrome incidence in
33 Japanese adults. *PLoS One*. 2023;18(4):e0284139.
- 34 11. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical
35 statistics. *Bone Marrow Transplant*. 2013;48(3):452-8.
- 36 12. Ogawa Y, Amano K, Matsuo-Tezuka Y, Okada N, Murakami Y, Nakamura T, et al.
37 ORIHIME study: real-world treatment patterns and clinical outcomes of 338 patients with
38 acquired hemophilia A from a Japanese administrative database. *Int J Hematol*.
39 2023;117(1):44-55.

40